Weekly Pharma & Life Science News Round-Up: 17th-21st October
A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 17th-21st October 2022.
Gilead Sciences, Inc. and MacroGenics announce an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs.
GSK plc and Tempus, a US-based precision medicine company, have entered into a three-year collaboration agreement that provides GSK with access to Tempus’ AI-enabled platform, including its library of de-identified patient data.
Eli Lilly and Company and Akouos, Inc. announce a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.
University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world.
AbbVie announce the acquisition of DJS Antibodies Ltd, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins such as G protein-coupled receptors (GPCRs).
Cegedim, the innovative technology, services, and health data company, announces the acquisition of Clinityx, an innovator in unlocking the full potential of health data in France.
It’s an exciting time for science thanks to Charles River Laboratories International, Inc. who have recently opened the doors to its new Cheshire site in Alderley Park.
Enhanc3D Genomics, a functional genomics company unlocking the full potential of the human 3D genome to transform therapeutic development, today announces it has raised £10 million in Series A financing to accelerate the development of its proprietary technology platform – “GenLink3DTM”.
Chiesi and Aptar Digital Health announce a strategic partnership to bring to market Aptar’s recently announced Disease Management Platform for asthma and chronic obstructive pulmonary disease (COPD).
Advanced Clinical, a clinical development and strategic resourcing organization, is pleased to join the Swiss Biotech Association, a non-profit organization representing the interests of the Swiss biotech industry.
Phesi, a global provider of patient-centric data analytics, has launched its AI-driven Trial Accelerator™ platform to facilitate real-time scenario modelling across patient, endpoint, country, KOL and investigator site allocation.
Evotec SE and Toronto Innovation Acceleration Partners (“TIAP”) announce that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner.
Health Education England has given digital innovation in the future workforce a boost with the injection of funding to support a new generation of digital health professionals. The Baker Dearing Education Trust has been awarded £52,000 to support a new generation of digital health professionals.
Kuros Biosciences announces that it has received the 2022 Spine Technology Award from the widely-read industry publication Orthopedics This Week for its MagnetOs Flex Matrix, a bone graft extender for use in the posterolateral spine.
AMSilk GmbH announces its relocation to a new biotech lab and office space covering more than 2000m2 on the recently constructed Campus Neuried in Munich, Germany, to support its expansion into production networks outside of Europe.